Developer docs
API playgroundTry for free, no card

Search company profiles

Ottimo Pharma

Full company profile

uuid0000lv5

Namestring
Ottimo Pharma
Legal namestring
Ottimo Pharma Limited
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Ottimo Pharma is a clinical-stage biotechnology company developing first-in-class PD-1/VEGFR2 dual-paratopic antibodies for the treatment of solid tumor cancers. The company's lead and effectively sole clinical asset is Jankistomig (also designated OTP-01), an Fc-null IgG1 monoclonal antibody featuring a proprietary dual-paratopic (biparatopic) architecture that simultaneously engages the PD-1 immune checkpoint and the VEGFR-2 angiogenic pathway within the tumor microenvironment. The molecule is designed for tumor microenvironment-biased distribution, allosteric VEGFR2 inhibition targeting ligands A/C/D, reduced systemic Avastin-like toxicity, and conventional IgG manufacturability and stability, positioning it as a potential combination backbone with ADCs or chemotherapy. The asset is investigational; Ottimo is pre-revenue and does not currently sell any product.

The company is UK-registered (Ottimo Pharma Limited, company number 10650475) with its registered office in Sandwich, Kent and operational presence in Boston, Massachusetts. It was co-founded in 2020 by Medicxi and scientific founder Jonny Finlay, operated in stealth for approximately three years, and emerged publicly in October 2024 under Chair & CEO David Epstein (former CEO of Seagen and Novartis Pharmaceuticals). The $140M+ Series A closed in December 2024 funded a Phase I/IIA adaptive trial; FDA IND clearance was secured in January 2026, the first patient was dosed, and the study is running across leading oncology centers in the US and Australia with planned expansion to approximately 20 centers globally. All clinical manufacturing of OTP-01 is conducted in the US via an expanded partnership with Lotte Biologics at its Syracuse Bio Campus.

The business model is a standard clinical-stage biotech construct: future revenue is expected from product sales upon regulatory approval or, alternatively, from strategic partnership/licensing transactions with major pharmaceutical companies covering co-development and commercialization rights, with no current pricing model in place. The target customer is ultimately oncology patients with solid tumors, particularly those who may benefit from combined PD-1 and anti-angiogenic therapy; in the near term, the company serves clinical trial investigators and sites. Manufacturing is single-source through Lotte Biologics, creating a known supply-chain concentration that will need to be de-risked as the asset advances.

Short descriptiontext

Ottimo Pharma is a clinical-stage biotechnology company developing a first-in-class PD-1/VEGFR2 dual-paratopic antibody (Jankistomig/OTP-01) for solid tumor cancers, currently in Phase I/IIA clinical trials across the US and Australia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSandwich, United Kingdom
HQ citystring
Sandwich
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology drug development, antibody therapeutics, cancer immunotherapy, bispecific antibodies, biotech research
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Oncology Biologics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company developing novel antibody therapeutics for cancer. Expected to generate revenue through product sales following regulatory approval or through strategic partnerships/licensing deals with major pharmaceutical companies for co-development and commercialization rights.

ottimopharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ottimo Pharma is a clinical-stage biotech company developing OTP-01 (Jankistomig), a first-in-class Fc-null IgG1 monoclonal antibody featuring a dual-paratopic design that simultaneously engages the PD-1 immune checkpoint and the VEGFR-2 angiogenic pathway for the treatment of solid tumors. The company is advancing the candidate through Phase I/IIA clinical trials and plans eventual commercialization through partnership with major pharmaceutical companies or independent launch.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Significantly improved anti-tumor efficacy compared to PD-1 inhibition alone in preclinical studies
+2 more records
Product overview1 text field

Ottimo Pharma is a clinical-stage biotech company developing a single lead product, Jankistomig (also referred to as OTP-01), a first-in-class PD-1/VEGFR2 dual-paratopic antibody for multiple solid tumor indications. The product is designed as a single-agent IgG1 therapy combining immune checkpoint inhibition with angiogenesis targeting in one molecule, offering a differentiated approach from traditional bispecific antibody fusions.

Product and service1 record
1OTP-01 (Jankistomig)
CategoryOncology Biologics
Description

A first-in-class, investigational Fc-null, IgG1 monoclonal antibody featuring a unique dual-paratopic design enabling simultaneous engagement of the PD-1 immune checkpoint and VEGFR-2 angiogenic pathway. Designed as a single-agent therapy for solid tumors that delivers cooperative binding of immune checkpoint inhibition and angiogenesis in the tumor microenvironment.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-18
Description

Expanded partnership with UK-based Lotte Biologics for antibody drug manufacturing and process development. Lotte Biologics will produce the active pharmaceutical ingredient (DS) for Ottimo's biparatopic antibody candidate Jankistomig (OTP-01) at its Syracuse Bio Campus in New York. The deal extends beyond simple manufacturing to include process development, marking deeper integration into Ottimo's drug development pipeline with potential for long-term commercialization cooperation. The partnership reflects Ottimo's confidence in Lotte Biologics' manufacturing capabilities and quality standards.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

China-based biotech that developed ivonescimab, a PD-1/VEGF bispecific antibody approved in China and with positive Phase III data in NSCLC. Akeso is the most direct competitor to Ottimo's PD-1/VEGFR2 dual mechanism, and its clinical/commercial progress directly benchmarks OTP-01's potential.

TypeDirect peer
Description

Clinical-stage immuno-oncology company using a computational biology platform to discover novel drug targets and develop antibody therapeutics. Comparable to Ottimo as a platform-driven oncology antibody developer focused on novel immune mechanisms.

TypeDirect peer
Description

Clinical-stage oncology company developing Probody therapeutics — masked antibodies designed to be activated in the tumor microenvironment. Comparable to Ottimo as a clinical-stage antibody platform company engineering tumor-microenvironment-biased activity.

TypeDirect peer
Description

Clinical-stage oncology company developing immune-stimulating antibody conjugates (ISACs) that combine tumor-targeting antibodies with immune agonists. Comparable as a clinical-stage antibody-platform company focused on novel immuno-oncology mechanisms.

TypeDirect peer
Description

Clinical-stage oncology company developing conditionally activated INDUKINE therapeutics designed to be activated in the tumor microenvironment. Comparable to Ottimo as a clinical-stage developer of engineered antibody-based cancer therapies with novel selectivity mechanisms.

TypeDirect peer
Description

Clinical-stage biotech developing bispecific antibodies and antibody-based therapeutics for cancer, including PD-1- and VEGF-related programs. Comparable to Ottimo as a developer of multi-specific antibody oncology therapeutics.

TypeDirect peer
Description

Clinical-stage oncology company developing antibody-drug conjugates and immunotherapies. Comparable to Ottimo as a clinical-stage antibody-platform company building combination-ready oncology therapeutics.

TypeDirect peer
Description

Clinical-stage oncology company developing a diversified pipeline of immuno-oncology and targeted therapeutics. Comparable to Ottimo as a clinical-stage biotech with a lead oncology asset advancing through early-phase trials with similar development-stage risk profile.

TypeDirect peer
Description

Clinical-stage oncology company developing novel antibody-drug conjugates using its Dolasynthen and Immunosynthen platforms. Comparable to Ottimo as a clinical-stage antibody-platform company developing next-generation cancer therapeutics with platform extensibility.

TypeEmerging player
Description

Clinical-stage biotech developing T cell engager (TCE) immunotherapies for cancer using a tumor-activated technology platform. Comparable to Ottimo as an early-stage oncology antibody company engineering safer, more selective cancer immunotherapies.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ottimo Pharma

Oncology Biologicsottimopharma.com

Ottimo Pharma is a clinical-stage biotechnology company developing a first-in-class PD-1/VEGFR2 dual-paratopic antibody (Jankistomig/OTP-01) for solid tumor cancers, currently in Phase I/IIA clinical trials across the US and Australia.

What Ottimo Pharma does

Ottimo Pharma is a clinical-stage biotechnology company developing first-in-class PD-1/VEGFR2 dual-paratopic antibodies for the treatment of solid tumor cancers. The company's lead and effectively sole clinical asset is Jankistomig (also designated OTP-01), an Fc-null IgG1 monoclonal antibody featuring a proprietary dual-paratopic (biparatopic) architecture that simultaneously engages the PD-1 immune checkpoint and the VEGFR-2 angiogenic pathway within the tumor microenvironment. The molecule is designed for tumor microenvironment-biased distribution, allosteric VEGFR2 inhibition targeting ligands A/C/D, reduced systemic Avastin-like toxicity, and conventional IgG manufacturability and stability, positioning it as a potential combination backbone with ADCs or chemotherapy. The asset is investigational; Ottimo is pre-revenue and does not currently sell any product.

The company is UK-registered (Ottimo Pharma Limited, company number 10650475) with its registered office in Sandwich, Kent and operational presence in Boston, Massachusetts. It was co-founded in 2020 by Medicxi and scientific founder Jonny Finlay, operated in stealth for approximately three years, and emerged publicly in October 2024 under Chair & CEO David Epstein (former CEO of Seagen and Novartis Pharmaceuticals). The $140M+ Series A closed in December 2024 funded a Phase I/IIA adaptive trial; FDA IND clearance was secured in January 2026, the first patient was dosed, and the study is running across leading oncology centers in the US and Australia with planned expansion to approximately 20 centers globally. All clinical manufacturing of OTP-01 is conducted in the US via an expanded partnership with Lotte Biologics at its Syracuse Bio Campus.

The business model is a standard clinical-stage biotech construct: future revenue is expected from product sales upon regulatory approval or, alternatively, from strategic partnership/licensing transactions with major pharmaceutical companies covering co-development and commercialization rights, with no current pricing model in place. The target customer is ultimately oncology patients with solid tumors, particularly those who may benefit from combined PD-1 and anti-angiogenic therapy; in the near term, the company serves clinical trial investigators and sites. Manufacturing is single-source through Lotte Biologics, creating a known supply-chain concentration that will need to be de-risked as the asset advances.

Ottimo Pharma firmographics

Firmographics
Name
Ottimo Pharma
Legal name
Ottimo Pharma Limited
Website
https://ottimopharma.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Ottimo Pharma is a clinical-stage biotechnology company developing a first-in-class PD-1/VEGFR2 dual-paratopic antibody (Jankistomig/OTP-01) for solid tumor cancers, currently in Phase I/IIA clinical trials across the US and Australia.
Ownership category
akta.pro rank

Where Ottimo Pharma is headquartered

Location

Headquarters

HQ city
Sandwich
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Ottimo Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Development and Commercialization: Pre-revenue clinical-stage biotech company developing novel antibody therapeutics for cancer. Expected to generate revenue through product sales following regulatory approval or through strategic partnerships/licensing deals with major pharmaceutical companies for co-development and commercialization rights.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Ottimo Pharma product offering

Product offering

Core offering

Ottimo Pharma is a clinical-stage biotech company developing OTP-01 (Jankistomig), a first-in-class Fc-null IgG1 monoclonal antibody featuring a dual-paratopic design that simultaneously engages the PD-1 immune checkpoint and the VEGFR-2 angiogenic pathway for the treatment of solid tumors. The company is advancing the candidate through Phase I/IIA clinical trials and plans eventual commercialization through partnership with major pharmaceutical companies or independent launch.

Product overview

Ottimo Pharma is a clinical-stage biotech company developing a single lead product, Jankistomig (also referred to as OTP-01), a first-in-class PD-1/VEGFR2 dual-paratopic antibody for multiple solid tumor indications. The product is designed as a single-agent IgG1 therapy combining immune checkpoint inhibition with angiogenesis targeting in one molecule, offering a differentiated approach from traditional bispecific antibody fusions.

Differentiator

Problem solved

Functional benefit

Products and services

  • OTP-01 (Jankistomig) A first-in-class, investigational Fc-null, IgG1 monoclonal antibody featuring a unique dual-paratopic design enabling simultaneous engagement of the PD-1 immune checkpoint and VEGFR-2 angiogenic pathway. Designed as a single-agent therapy for solid tumors that delivers cooperative binding of immune checkpoint inhibition and angiogenesis in the tumor microenvironment.

Quantifiable outcome

  • Significantly improved anti-tumor efficacy compared to PD-1 inhibition alone in preclinical studies
  • +2 more outcomes

Companies that use Ottimo Pharma

Customer profile

Segments1 record

Ideal customer profiles2 records

Ottimo Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Ottimo Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Lotte BiologicscoreStrategic or Co-development Partner · 18 May 2026Expanded partnership with UK-based Lotte Biologics for antibody drug manufacturing and process development. Lotte Biologics will produce the active pharmaceutical ingredient (DS) for Ottimo's biparatopic antibody candidate Jankistomig (OTP-01) at its Syracuse Bio Campus in New York. The deal extends beyond simple manufacturing to include process development, marking deeper integration into Ottimo's drug development pipeline with potential for long-term commercialization cooperation. The partnership reflects Ottimo's confidence in Lotte Biologics' manufacturing capabilities and quality standards.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Ottimo Pharma competitors and assessment

Company assessment

Direct peers

  • Akeso: China-based biotech that developed ivonescimab, a PD-1/VEGF bispecific antibody approved in China and with positive Phase III data in NSCLC. Akeso is the most direct competitor to Ottimo's PD-1/VEGFR2 dual mechanism, and its clinical/commercial progress directly benchmarks OTP-01's potential.
  • Compugen: Clinical-stage immuno-oncology company using a computational biology platform to discover novel drug targets and develop antibody therapeutics. Comparable to Ottimo as a platform-driven oncology antibody developer focused on novel immune mechanisms.
  • CytomX Therapeutics: Clinical-stage oncology company developing Probody therapeutics — masked antibodies designed to be activated in the tumor microenvironment. Comparable to Ottimo as a clinical-stage antibody platform company engineering tumor-microenvironment-biased activity.
  • Bolt Biotherapeutics: Clinical-stage oncology company developing immune-stimulating antibody conjugates (ISACs) that combine tumor-targeting antibodies with immune agonists. Comparable as a clinical-stage antibody-platform company focused on novel immuno-oncology mechanisms.
  • Werewolf Therapeutics: Clinical-stage oncology company developing conditionally activated INDUKINE therapeutics designed to be activated in the tumor microenvironment. Comparable to Ottimo as a clinical-stage developer of engineered antibody-based cancer therapies with novel selectivity mechanisms.
  • MacroGenics: Clinical-stage biotech developing bispecific antibodies and antibody-based therapeutics for cancer, including PD-1- and VEGF-related programs. Comparable to Ottimo as a developer of multi-specific antibody oncology therapeutics.
  • Pyxis Oncology: Clinical-stage oncology company developing antibody-drug conjugates and immunotherapies. Comparable to Ottimo as a clinical-stage antibody-platform company building combination-ready oncology therapeutics.
  • Cullinan Oncology: Clinical-stage oncology company developing a diversified pipeline of immuno-oncology and targeted therapeutics. Comparable to Ottimo as a clinical-stage biotech with a lead oncology asset advancing through early-phase trials with similar development-stage risk profile.
  • Mersana Therapeutics: Clinical-stage oncology company developing novel antibody-drug conjugates using its Dolasynthen and Immunosynthen platforms. Comparable to Ottimo as a clinical-stage antibody-platform company developing next-generation cancer therapeutics with platform extensibility.

Emerging players

  • Janux Therapeutics: Clinical-stage biotech developing T cell engager (TCE) immunotherapies for cancer using a tumor-activated technology platform. Comparable to Ottimo as an early-stage oncology antibody company engineering safer, more selective cancer immunotherapies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Ottimo Pharma social profiles

Digital presence

Ottimo Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ottimo Pharma leadership team

Management profile

Number of profiles

Profiles14 records

Ottimo Pharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ottimo Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ottimo Pharma

What does Ottimo Pharma do?

Ottimo Pharma is a clinical-stage biotech company developing OTP-01 (Jankistomig), a first-in-class Fc-null IgG1 monoclonal antibody featuring a dual-paratopic design that simultaneously engages the PD-1 immune checkpoint and the VEGFR-2 angiogenic pathway for the treatment of solid tumors. The company is advancing the candidate through Phase I/IIA clinical trials and plans eventual commercialization through partnership with major pharmaceutical companies or independent launch.

Is Ottimo Pharma a public or private company?

Ottimo Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ottimo Pharma founded?

Ottimo Pharma was founded in 2020. It employs 11 to 50 people.

Where is Ottimo Pharma based?

Ottimo Pharma is headquartered in Sandwich, United Kingdom, in the Europe region.

How does Ottimo Pharma make money?

One revenue line is on record: pharmaceutical Development and Commercialization.

Who are Ottimo Pharma's main competitors?

Direct peers on record are Akeso, Compugen, CytomX Therapeutics, Bolt Biotherapeutics, Werewolf Therapeutics, MacroGenics, Pyxis Oncology, Cullinan Oncology and Mersana Therapeutics. Janux Therapeutics is listed as an emerging player.

Does Ottimo Pharma have an API?

No public API is recorded for Ottimo Pharma.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Korea HeraldLotte Biologics, Ottimo Pharma expand antibody manufacturing partnershipLotte Biologics signed a contract manufacturing agreement with UK biotech firm Ottimo Pharma to produce the active pharmaceutical ingredient for Jankistomig, Ottimo Pharma's biparatopic antibody candidate, at its Syracuse Bio Campus in New York. The deal expands their existing antibody development partnership from June last year into broader manufacturing, development, and commercialization cooperation. Lotte Biologics plans to complete its dual-site strategy later this year by finishing Plant 1 at its Songdo Bio Campus in Incheon, creating a manufacturing network spanning North America and Asia.PR NewswireLOTTE Biologics Expands Antibody Manufacturing Agreement with Ottimo PharmaLOTTE Biologics announced an expansion of its antibody development and manufacturing agreement with Ottimo Pharma, building on an original agreement signed in June of the previous year. The expanded partnership will support Ottimo Pharma's biparatopic antibody OTP-01 through commercial process development and characterization activities at LOTTE Biologics' Syracuse Bio Campus in New York. This collaboration reinforces LOTTE Biologics' position as a CDMO supporting clients from clinical development through commercialization, highlighting the growing strategic relationship between the two companies.PR NewswireLOTTE Biologics Expands Antibody Manufacturing Agreement with Ottimo PharmaLOTTE Biologics announced an expansion of its collaboration with Ottimo Pharma for antibody manufacturing and development, building on an agreement signed in June 2025. The extended partnership will leverage LOTTE's Syracuse Bio Campus in New York to support commercial process development for Ottimo's biparatopic antibody OTP-01 targeting PD-1/VEGFR2, advancing it toward launch readiness. Both companies described the expansion as reflecting Ottimo Pharma's confidence in LOTTE Biologics' quality and execution capabilities.BioSpaceFrontier Medicines Appoints Veteran Drug Development Leader David R. Epstein to Board of DirectorsFrontier Medicines appointed David R. Epstein to its board of directors. Epstein, currently CEO of Ottimo Pharma, previously led Seagen and Novartis, and brings over 30 years of drug development experience. He will support Frontier's pipeline of covalent precision medicines, including FMC-242 and FMC-376.GlobeNewswireOttimo Pharma Announces FDA Clearance of Investigational New Drug (IND) Application for OTP-01, a First-in-Class, Dual-Paratopic, Single-Agent, Anti-PD-1/VEGFR2 AntibodyOttimo Pharma received FDA clearance for its lead candidate OTP-01, a dual-PD-1/VEGFR2 antibody, with the first patient dosed and recruitment underway. The Phase I/IIA study will assess safety, tolerability, and early efficacy in US and Australian centers. The company aims to expand to about 20 global centers.PR NewswireLOTTE BIOLOGICS Signs Antibody Manufacturing Contract with Ottimo PharmaLOTTE BIOLOGICS signed a contract manufacturing agreement with Ottimo Pharma for antibody drug substance for Jankistomig at its Syracuse Bio Campus. The deal supports Ottimo's path to IND submission and clinical trial initiation. LOTTE BIOLOGICS plans to begin operation of Plant 1 at its Songdo Bio Campus in 2027.PR NewswireLOTTE BIOLOGICS Signs Antibody Manufacturing Contract with Ottimo PharmaLOTTE BIOLOGICS signed a contract manufacturing agreement with Ottimo Pharma for antibody drug substance for Jankistomig at its Syracuse Bio Campus in New York. The deal marks further validation of LOTTE's competitiveness as a CDMO in antibody therapeutics. LOTTE aims to begin operation of Plant 1 at its Songdo Bio Campus in 2027.GlobeNewswireOttimo Pharma Strengthens Board with Appointment of Roger Dansey, M.D. to its Board of DirectorsOttimo Pharma appointed Roger Dansey, M.D., to its board of directors. Dansey, a former Pfizer and Seagen executive, will support advancing Jankistomig, a PD-1/VEGFR2 dual antibody, with IND clearance planned for late 2025.CapitalOttimo набира 140 млн. долара за иновативни лекарства за лечение на ракOttimo Pharma raised $140 million in early funding for its cancer drug Jankistomig, which combines anti-PD-1 and anti-VEGF molecules. The company aims to replace existing treatments, and the market for this drug class is expected to reach $100 billion annually.Pulse 2.0Ottimo Pharma: Over $140 Million (Series A) Raised To Advance Bifunctional MedicinesOttimo Pharma raised over $140 million in a Series A led by OrbiMed, Avoro Capital, and Samsara BioCapital. The funding will advance Jankistomig, a PD1/VEGFR2 bifunctional antibody, with an IND filing planned in late 2025. The company also expanded its management team.